ABT
ABBOTT LABORATORIES
NYSE · Healthcare · Medical - Devices · US
$115.52
+5.59%Sep 15, 2026, 10:18 UTC
Flex Ltd. appointed Brian Yoor as a member of its Board of Directors.
Sep 9, 2026, 15:31 UTC
Abbott received FDA approval for its TactiFlex Duo catheter, expanding its atrial fibrillation ablation portfolio with dual PFA and RF energy options in the United States.
Source:Aug 31, 2026, 12:00 UTC
Abbott launched Similac 360 Total Care Made With Whole Milk, the first and only ready-to-feed liquid infant formula made with whole milk in the U.S., at a price similar to its existing Similac powdered formula, available online and at major U.S. retailers.
Source:Aug 28, 2026, 00:18 UTC
China's National Healthcare Security Administration held a symposium on August 27, 2026, with 16 pharmaceutical companies to discuss industry development and gather opinions for the 15th Five-Year Plan period.
Source:Aug 27, 2026, 13:03 UTC
Abbott's next-generation Amulet 360™ occluder received CE marking for treating atrial fibrillation patients at risk of stroke.
Aug 25, 2026, 08:09 UTC
Gateway Wealth Partners LLC reduced its stake in Abbott Laboratories by 64.3% during the quarter, selling 15,431 shares and retaining 8,564 shares, according to a recent SEC filing.
Source:Aug 25, 2026, 08:09 UTC
Choreo LLC reduced its stake in Abbott Laboratories by 4.4% during the second quarter, selling 4,580 shares, as disclosed in its 13F filing.
Source:Aug 25, 2026, 08:09 UTC
Golden Reserve Retirement LLC increased its stake in Abbott Laboratories by 155.2% during the quarter, acquiring 5,557 additional shares to hold 9,138 shares, as disclosed in its Form 13F filing.
Source:Aug 20, 2026, 19:51 UTC
HealthTab, a subsidiary of Avricore Health, signed a distribution agreement with Abbott to supply and distribute Abbott's point-of-care testing products, including the Afinion 2 Analyzer, in the UK.
Source:Aug 17, 2026, 09:56 UTC
Fifth Third Wealth Advisors LLC reduced its holdings in Abbott Laboratories by 32.6% during the second quarter, selling 14,830 shares and retaining 30,646 shares, as disclosed in its Form 13F filing.
Source:Aug 11, 2026, 13:02 UTC
Abbott announced a partnership with Google to conduct a large-scale metabolic health research study.
Jul 27, 2026, 12:00 UTC
The FDA approved Freenome's SimpleScreen CRC blood-based screening test, and Abbott will commercialize it in the U.S.
Source:Jul 24, 2026, 19:58 UTC
A patient filed a class action lawsuit against Abbott Laboratories and Exact Sciences in Illinois federal court, alleging failure to safeguard sensitive personal and health information in a data theft hack claimed by ShinyHunters.
Source:Jul 16, 2026, 12:35 UTC
Abbott's cancer diagnostics business suffered a cybersecurity incident; the incident did not affect operations or product supply.
Jul 16, 2026, 00:00 UTC
Abbott Laboratories reported its Q2 2026 financial results, with revenue of $12.593 billion and GAAP diluted EPS of $0.53, and updated its full-year 2026 adjusted diluted EPS guidance to a range of $5.45 to $5.60.
Jun 29, 2026, 01:17 UTC
The U.S. Department of Justice closed a criminal probe into Abbott Laboratories over its management of a baby formula plant and opted for civil penalties instead.
Source:Jun 24, 2026, 11:36 UTC
ALZpath signed a global licensing agreement with Abbott Laboratories to develop a blood-based test for Alzheimer's disease.
Source:Jun 12, 2026, 18:29 UTC
Abbott's board of directors declared a quarterly common dividend of 63 cents per share.
Source:Jun 5, 2026, 17:57 UTC
A U.S. federal judge ruled that consumers could reasonably interpret Abbott's marketing of PediaSure as promising height growth, allowing a lawsuit to proceed.
Source:
← PreviousPage 2